VGR-R01
- Generic Name
- VGR-R01
Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients with Bietti Crystalline Dystrophy
Phase 3
Not yet recruiting
- Conditions
- Bietti Crystalline DystrophyInherited Retinal Diseases
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT06699108
- Locations
- 🇨🇳
Shanghai Vitalgen Biopharma Co.,Ltd., Shanghai, Shanghai, China
Safety and Tolerability of VGR-R01 in Patients With Bietti Crystalline Dystrophy
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT05399069
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath